Organization: Johns Hopkins

Canada can be a leader in delivering widespread, well-regulated psychedelic-assisted therapy for people with depression, anxiety, post-traumatic stress disorder and substance abuse, by investing in research, educating health care professionals and providing the necessary clinical infrastructure, Dr. Ross Marshall, chief scientific officer at The Newly Institute based in Calgary, says in an op-ed.